Ekso Total Current Assets vs Net Debt Analysis

EKSO Stock

USD 1.40 0.04 2.78%

Ekso Bionics financial indicator trend analysis is much more than just examining Ekso Bionics Holdings latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ekso Bionics Holdings is a good investment. Please check the relationship between Ekso Bionics Total Current Assets and its Net Debt accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ekso Bionics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

Total Current Assets vs Net Debt

Total Current Assets vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ekso Bionics Holdings Total Current Assets account and Net Debt. At this time, the significance of the direction appears to have pay attention.

The correlation between Ekso Bionics' Total Current Assets and Net Debt is -0.87. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Net Debt in the same time period over historical financial statements of Ekso Bionics Holdings, assuming nothing else is changed. The correlation between historical values of Ekso Bionics' Total Current Assets and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Ekso Bionics Holdings are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Total Current Assets i.e., Ekso Bionics' Total Current Assets and Net Debt go up and down completely randomly.

Correlation Coefficient

-0.87

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from Ekso Bionics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ekso Bionics Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ekso Bionics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

As of the 15th of May 2024, Sales General And Administrative To Revenue is likely to grow to 1.01, while Selling General Administrative is likely to drop about 8.7 M.

	2021	2022	2023	2024 (projected)
Gross Profit	6.7M	6.2M	9.7M	5.1M
Total Revenue	11.2M	12.9M	18.3M	12.3M

Gross Profit Total Revenue

Ekso Bionics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Common Stock Shares Outstanding	Other Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt
Total Assets		0.53	0.75	0.83	0.9	-0.81	-0.74	0.93	0.92	0.33	0.61	0.77	0.99	0.38	0.37	0.44	0.81	-0.02	0.09	0.19	-0.55	0.74	0.16	-0.54	-0.56	0.36
Short Long Term Debt Total	0.53		0.76	0.69	0.33	-0.05	-0.75	0.32	0.31	-0.09	0.49	0.63	0.47	0.72	-0.06	0.44	0.76	-0.4	-0.28	0.53	-0.86	0.59	0.27	-0.87	-0.88	0.74
Other Current Liab	0.75	0.76		0.89	0.52	-0.44	-0.69	0.64	0.62	0.38	0.63	0.81	0.72	0.51	0.41	0.2	0.71	-0.17	-0.32	0.24	-0.73	0.71	0.03	-0.71	-0.73	0.54
Total Current Liabilities	0.83	0.69	0.89		0.56	-0.47	-0.8	0.65	0.63	0.52	0.7	0.9	0.78	0.68	0.56	0.31	0.82	0.01	-0.35	0.42	-0.63	0.83	0.21	-0.64	-0.66	0.39
Total Stockholder Equity	0.9	0.33	0.52	0.56		-0.84	-0.56	0.92	0.9	0.12	0.23	0.41	0.92	0.23	0.17	0.48	0.65	-0.25	0.48	0.03	-0.41	0.56	0.09	-0.4	-0.44	0.14
Net Debt	-0.81	-0.05	-0.44	-0.47	-0.84		0.29	-0.93	-0.96	-0.39	-0.34	-0.44	-0.87	0.05	-0.41	-0.05	-0.42	-0.19	-0.31	0.29	0.2	-0.44	0.2	0.18	0.15	-0.04
Retained Earnings	-0.74	-0.75	-0.69	-0.8	-0.56	0.29		-0.55	-0.49	-0.02	-0.6	-0.74	-0.7	-0.65	-0.07	-0.75	-0.98	0.23	0.19	-0.36	0.79	-0.75	-0.18	0.83	0.83	-0.62
Cash	0.93	0.32	0.64	0.65	0.92	-0.93	-0.55		0.99	0.31	0.48	0.6	0.97	0.15	0.34	0.27	0.63	0.02	0.22	-0.11	-0.46	0.62	-0.11	-0.43	-0.42	0.26
Cash And Short Term Investments	0.92	0.31	0.62	0.63	0.9	-0.96	-0.49	0.99		0.34	0.46	0.59	0.96	0.14	0.37	0.19	0.6	0.07	0.23	-0.14	-0.42	0.58	-0.12	-0.4	-0.38	0.24
Common Stock Total Equity	0.33	-0.09	0.38	0.52	0.12	-0.39	-0.02	0.31	0.34		0.39	0.49	0.31	0.22	1.0	-0.47	0.07	0.5	-0.39	0.07	0.14	0.18	-0.06	0.13	0.13	-0.28
Non Current Liabilities Total	0.61	0.49	0.63	0.7	0.23	-0.34	-0.6	0.48	0.46	0.39		0.94	0.55	0.21	0.41	0.13	0.59	0.52	-0.58	0.27	-0.4	0.55	0.18	-0.39	-0.35	0.59
Total Liab	0.77	0.63	0.81	0.9	0.41	-0.44	-0.74	0.6	0.59	0.49	0.94		0.71	0.46	0.52	0.22	0.75	0.32	-0.52	0.36	-0.54	0.73	0.21	-0.54	-0.52	0.54
Total Current Assets	0.99	0.47	0.72	0.78	0.92	-0.87	-0.7	0.97	0.96	0.31	0.55	0.71		0.32	0.35	0.39	0.77	-0.03	0.14	0.04	-0.56	0.71	0.01	-0.54	-0.55	0.34
Short Term Debt	0.38	0.72	0.51	0.68	0.23	0.05	-0.65	0.15	0.14	0.22	0.21	0.46	0.32		0.24	0.37	0.65	-0.34	-0.29	0.61	-0.64	0.59	0.24	-0.68	-0.71	0.24
Common Stock	0.37	-0.06	0.41	0.56	0.17	-0.41	-0.07	0.34	0.37	1.0	0.41	0.52	0.35	0.24		-0.42	0.11	0.48	-0.38	0.1	0.12	0.22	-0.03	0.11	0.1	-0.27
Common Stock Shares Outstanding	0.44	0.44	0.2	0.31	0.48	-0.05	-0.75	0.27	0.19	-0.47	0.13	0.22	0.39	0.37	-0.42		0.7	-0.46	0.28	0.33	-0.48	0.48	0.37	-0.52	-0.58	0.34
Other Stockholder Equity	0.81	0.76	0.71	0.82	0.65	-0.42	-0.98	0.63	0.6	0.07	0.59	0.75	0.77	0.65	0.11	0.7		-0.2	-0.12	0.33	-0.78	0.77	0.17	-0.83	-0.82	0.59
Other Liab	-0.02	-0.4	-0.17	0.01	-0.25	-0.19	0.23	0.02	0.07	0.5	0.52	0.32	-0.03	-0.34	0.48	-0.46	-0.2		-0.44	-0.14	0.43	-0.03	-0.04	0.44	0.52	-0.13
Net Tangible Assets	0.09	-0.28	-0.32	-0.35	0.48	-0.31	0.19	0.22	0.23	-0.39	-0.58	-0.52	0.14	-0.29	-0.38	0.28	-0.12	-0.44		-0.29	0.25	-0.19	0.04	0.22	0.15	-0.37
Property Plant And Equipment Net	0.19	0.53	0.24	0.42	0.03	0.29	-0.36	-0.11	-0.14	0.07	0.27	0.36	0.04	0.61	0.1	0.33	0.33	-0.14	-0.29		-0.2	0.32	0.84	-0.21	-0.29	0.12
Current Deferred Revenue	-0.55	-0.86	-0.73	-0.63	-0.41	0.2	0.79	-0.46	-0.42	0.14	-0.4	-0.54	-0.56	-0.64	0.12	-0.48	-0.78	0.43	0.25	-0.2		-0.66	0.15	0.99	0.96	-0.71
Accounts Payable	0.74	0.59	0.71	0.83	0.56	-0.44	-0.75	0.62	0.58	0.18	0.55	0.73	0.71	0.59	0.22	0.48	0.77	-0.03	-0.19	0.32	-0.66		0.15	-0.63	-0.66	0.32
Non Current Assets Total	0.16	0.27	0.03	0.21	0.09	0.2	-0.18	-0.11	-0.12	-0.06	0.18	0.21	0.01	0.24	-0.03	0.37	0.17	-0.04	0.04	0.84	0.15	0.15		0.13	0.03	-0.03
Non Currrent Assets Other	-0.54	-0.87	-0.71	-0.64	-0.4	0.18	0.83	-0.43	-0.4	0.13	-0.39	-0.54	-0.54	-0.68	0.11	-0.52	-0.83	0.44	0.22	-0.21	0.99	-0.63	0.13		0.98	-0.71
Other Assets	-0.56	-0.88	-0.73	-0.66	-0.44	0.15	0.83	-0.42	-0.38	0.13	-0.35	-0.52	-0.55	-0.71	0.1	-0.58	-0.82	0.52	0.15	-0.29	0.96	-0.66	0.03	0.98		-0.61
Long Term Debt	0.36	0.74	0.54	0.39	0.14	-0.04	-0.62	0.26	0.24	-0.28	0.59	0.54	0.34	0.24	-0.27	0.34	0.59	-0.13	-0.37	0.12	-0.71	0.32	-0.03	-0.71	-0.61

Click cells to compare fundamentals

Ekso Bionics Account Relationship Matchups

Ekso Bionics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	21.9M	20.6M	49.2M	40.9M	28.9M	26.0M
Short Long Term Debt Total	3.9M	3.9M	2.2M	7.5M	7.2M	3.7M
Other Current Liab	1.7M	1.4M	2.3M	2.3M	2.7M	2.3M
Total Current Liabilities	7.8M	5.0M	6.9M	9.2M	8.1M	6.6M
Total Stockholder Equity	6.8M	4.4M	37.2M	25.4M	12.6M	13.6M
Net Debt	(7M)	(9.0M)	(38.2M)	(13.0M)	(1.5M)	(1.5M)
Retained Earnings	(183.3M)	(199.1M)	(208.9M)	(223.9M)	(239.1M)	(227.2M)
Cash	10.9M	12.9M	40.4M	20.5M	8.6M	16.1M
Cash And Short Term Investments	10.9M	12.9M	40.4M	20.5M	8.6M	8.2M
Common Stock Total Equity	60K	63K	87K	8K	9.2K	8.7K
Liabilities And Stockholders Equity	21.9M	20.6M	49.2M	40.9M	28.9M	26.0M
Non Current Liabilities Total	7.3M	11.2M	5.1M	6.3M	8.2M	7.4M
Total Liab	15.1M	16.2M	11.9M	15.5M	16.3M	13.4M
Total Current Assets	18.8M	18.4M	47.8M	31.0M	20.2M	22.1M
Short Term Debt	2.8M	548K	229K	2.7M	1.6M	1.1M
Common Stock	63K	87K	8K	13K	15K	14.3K
Common Stock Shares Outstanding	4.8M	7.2M	12.3M	13.0M	13.9M	14.6M
Other Stockholder Equity	189.9M	204.4M	246.1M	248.8M	251.6M	179.6M
Other Liab	6.2M	7.9M	3.1M	1.4M	1.3M	1.2M
Net Tangible Assets	6.6M	4.4M	37.2M	19.8M	22.8M	15.5M
Property Plant And Equipment Net	2.7M	1.9M	1.2M	4.0M	3.0M	2.7M
Current Deferred Revenue	1.5M	1.5M	1.2M	1.1M	2.0M	1.4M
Accounts Payable	1.9M	1.5M	3.1M	3.2M	1.8M	2.5M
Non Current Assets Total	3.1M	2.2M	1.4M	9.9M	8.7M	5.0M
Non Currrent Assets Other	178K	320K	164K	231K	392K	504.2K
Other Assets	134K	178K	1.0M	164K	147.6K	140.2K
Long Term Debt	407K	9.1M	2.0M	3.8M	4.8M	3.8M
Net Receivables	5.2M	3.4M	4.7M	4.6M	5.6M	3.9M
Long Term Debt Total	4.8M	2.6M	407K	9.1M	10.5M	11.0M
Capital Surpluse	165.8M	173.9M	189.9M	204.4M	235.0M	165.0M
Inventory	2.5M	2.0M	2.2M	5.2M	5.1M	2.9M
Other Current Assets	238K	191K	485K	700K	875K	597.9K
Property Plant And Equipment Gross	2.7M	1.9M	1.2M	4.0M	6.2M	6.5M
Accumulated Other Comprehensive Income	50K	(847K)	(17K)	563K	156K	163.8K
Property Plant Equipment	2.7M	1.2M	1.2M	4.0M	4.6M	2.6M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Ekso Bionics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Ekso Bionics' short interest history, or implied volatility extrapolated from Ekso Bionics options trading.

Pair Trading with Ekso Bionics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ekso Bionics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ekso Bionics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Ekso Stock

0.84

DRIO

DarioHealth Corp Earnings Call Today

Pair Corr

Moving against Ekso Stock

0.76	DXCM	DexCom Inc	Pair Corr
0.74	CI	Cigna Corp	Pair Corr
0.73	MCK	McKesson	Pair Corr
0.72	EDAP	EDAP TMS SA Earnings Call Tomorrow	Pair Corr
0.62	BSX	Boston Scientific Corp	Pair Corr

The ability to find closely correlated positions to Ekso Bionics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ekso Bionics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ekso Bionics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ekso Bionics Holdings to buy it.

The correlation of Ekso Bionics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ekso Bionics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ekso Bionics Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Ekso Bionics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Ekso Bionics Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ekso Bionics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ekso Bionics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ekso Bionics Holdings Stock:

How To Invest In Ekso

Details

Is Ekso Stock a good investment?

Details

What is Ekso Bionics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ekso Bionics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for Ekso Stock analysis

When running Ekso Bionics' price analysis, check to measure Ekso Bionics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ekso Bionics is operating at the current time. Most of Ekso Bionics' value examination focuses on studying past and present price action to predict the probability of Ekso Bionics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ekso Bionics' price. Additionally, you may evaluate how the addition of Ekso Bionics to your portfolios can decrease your overall portfolio volatility.

	Equity Valuation Check real value of public entities based on technical and fundamental data
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	CEOs Directory Screen CEOs from public companies around the world
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios

Is Ekso Bionics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ekso Bionics. If investors know Ekso will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ekso Bionics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.97)

Revenue Per Share

1.202

Quarterly Revenue Growth

(0.09)

Return On Assets

(0.26)

Return On Equity

(0.81)

The market value of Ekso Bionics Holdings is measured differently than its book value, which is the value of Ekso that is recorded on the company's balance sheet. Investors also form their own opinion of Ekso Bionics' value that differs from its market value or its book value, called intrinsic value, which is Ekso Bionics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ekso Bionics' market value can be influenced by many factors that don't directly affect Ekso Bionics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ekso Bionics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ekso Bionics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ekso Bionics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ekso Total Current Assets vs Net Debt Analysis

Total Current Assets vs Net Debt

Total Current Assets vs Net Debt Correlation Analysis

Correlation Coefficient

Total Current Assets

Net Debt

Ekso Bionics fundamental ratios Correlations

Ekso Bionics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ekso Bionics fundamental ratios Accounts

Pair Trading with Ekso Bionics

Moving together with Ekso Stock

Moving against Ekso Stock

Complementary Tools for Ekso Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Total Current Assets	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Cash
Non Currrent Assets Other	+ 0.99	Current Deferred Revenue
Other Assets	+ 0.98	Non Currrent Assets Other
Total Current Assets	+ 0.97	Cash

Other Stockholder Equity	- 0.98	Retained Earnings
Cash And Short Term Investments	- 0.96	Net Debt
Cash	- 0.93	Net Debt
Other Assets	- 0.88	Short Long Term Debt Total
Total Current Assets	- 0.87	Net Debt
Non Currrent Assets Other	- 0.87	Short Long Term Debt Total